Biocon Shares Rise 4% As Q1 Profit Jumps 53% To ₹137 Crore

Biocon Ltd has reported a 53.36% year-on-year increase in consolidated net profit to ₹136.8 crore for the first quarter of the financial year 2027. The company's biopharma business drove this growth, with a 17% year-on-year revenue increase.

The biopharma segment's revenue growth was supported by recent launches of biosimilar and generic products across key international markets. Revenue from biosimilars grew 16% year-on-year to ₹2,855 crore, while the generics business reported a 21% rise in revenue to ₹760 crore.

Biocon's consolidated total income increased to ₹4,390.5 crore in the April-June quarter from ₹4,021.6 crore in the year-ago period. However, total expenses also increased to ₹4,249.4 crore compared with ₹3,907.5 crore during the same period last year.

Following the earnings announcement, shares of Biocon rose nearly 4% on Thursday to trade at ₹441.85 apiece. Biocon Executive Chairperson Kiran Mazumdar-Shaw said the company has entered FY27 with a focus on converting strategic investments into sustainable growth and long-term value creation.

Mazumdar-Shaw added that favourable policy developments for biosimilars, along with expanded manufacturing capabilities in the US, strengthen the company's confidence in growth opportunities in North America, its largest market. The company expects stronger momentum in FY27, with investments in new capabilities within the research services business expected to support the next phase of expansion.

During the post-earnings conference call, Biocon management said the company began FY27 on a steady note and expects performance to improve through the year. The company expects momentum in its biosimilars business to strengthen further, with meaningful acceleration likely in the second half of FY27.

Biocon's expanded manufacturing infrastructure and product pipeline position it well to capture opportunities in global markets, particularly in biosimilars, where demand for affordable biologic medicines continues to rise. The company's strong Q1 performance is a positive sign for the biopharma industry, which is expected to continue growing in the coming years.

The increase in Biocon's shares is a reflection of the company's strong financial performance and its growth prospects. The company's focus on biopharma and its expansion into new markets are expected to drive growth in the coming years.

In terms of significance, Biocon's strong Q1 performance is a positive indicator for the Indian biopharma industry, which is expected to continue growing in the coming years. The company's focus on biopharma and its expansion into new markets are expected to drive growth in the coming years, making it an important player in the industry.

Overall, Biocon's Q1 performance is a strong indication of the company's growth prospects and its ability to drive revenue growth through its biopharma business. The company's expanded manufacturing infrastructure and product pipeline position it well to capture opportunities in global markets, particularly in biosimilars.